Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. Drugs used in
chemotherapy such as cladribine work in different ways to stop cancer cells from dividing so
they stop growing or die. Combining rituximab with cladribine may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with cladribine
works in treating patients with newly-diagnosed mantle cell lymphoma.